Fulcrum Therapeutics (NASDAQ:FULC) vs. Laboratorios Farmaceuticos Rovi (OTCMKTS:LABFF) Head-To-Head Comparison

Fulcrum Therapeutics (NASDAQ:FULC) and Laboratorios Farmaceuticos Rovi (OTCMKTS:LABFF) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their risk, dividends, institutional ownership, valuation, analyst recommendations, profitability and earnings.

Insider & Institutional Ownership

89.8% of Fulcrum Therapeutics shares are held by institutional investors. 2.5% of Fulcrum Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Earnings and Valuation

This table compares Fulcrum Therapeutics and Laboratorios Farmaceuticos Rovi’s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Fulcrum Therapeutics	$6.34 million	43.78	-$109.87 million	($1.80)	-2.49
Laboratorios Farmaceuticos Rovi	N/A	N/A	N/A	N/A	N/A

Laboratorios Farmaceuticos Rovi has lower revenue, but higher earnings than Fulcrum Therapeutics.

Profitability

This table compares Fulcrum Therapeutics and Laboratorios Farmaceuticos Rovi’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Fulcrum Therapeutics	-3,234.80%	-39.50%	-35.76%
Laboratorios Farmaceuticos Rovi	N/A	N/A	N/A

Analyst Recommendations

This is a summary of recent recommendations and price targets for Fulcrum Therapeutics and Laboratorios Farmaceuticos Rovi, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Fulcrum Therapeutics	1	3	4	0	2.38
Laboratorios Farmaceuticos Rovi	0	0	0	0	N/A

Fulcrum Therapeutics currently has a consensus target price of $11.25, suggesting a potential upside of 150.56%. Given Fulcrum Therapeutics’ higher possible upside, equities analysts plainly believe Fulcrum Therapeutics is more favorable than Laboratorios Farmaceuticos Rovi.

Summary

Fulcrum Therapeutics beats Laboratorios Farmaceuticos Rovi on 5 of the 8 factors compared between the two stocks.

About Fulcrum Therapeutics

Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy is under phase III clinical trial; and FTX-6058, an investigational oral fetal hemoglobin inducer for the treatment of sickle cell disease and other hemoglobinopathies, including beta-thalassemia is under phase I clinical trial. The company is also discovering drug targets for the treatments of rare neuromuscular, muscular, central nervous system, and hematologic disorders, as well as cardiomyopathies and pulmonary diseases. Fulcrum Therapeutics, Inc. has collaboration and license agreement with Acceleron Pharma Inc. to identify biological targets to modulate specific pathways associated with a targeted indication within the pulmonary disease space; and MyoKardia, Inc. to discover, develop, and commercialize novel targeted therapies for the treatment of genetic cardiomyopathies. Fulcrum Therapeutics, Inc. was Incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

About Laboratorios Farmaceuticos Rovi

Laboratorios Farmaceuticos Rovi, S.A. engages in the research, development, production, and sale of pharmaceutical products in Spain, European Union, OECD countries, and internationally. The company distributes other products that are licensed from other laboratories. Its principal products include Ameride, Bertanel, Bluxam, Enoxaparin Rovi, Calcium Vitamine D3 Rovi, Exxiv, Prinvil, Rhodogil, Glufan, Hibor, Hirobriz Breezhaler, Neparvis, Medicebran, Medikinet, Mysimba, Orvatez, Tryptizol, Ulunar Breezhaler, and Volutsa. It provides non-prescription pharmaceutical products; and contract-manufacturing services to other companies for a range of pharmaceutical forms, including prefilled syringes, vials, suppositories, tablets, hard capsules, and sachets. The company was incorporated in 1946 and is headquartered in Madrid, Spain. Laboratorios Farmaceúticos Rovi, S.A. is a subsidiary of Norbel Inversiones, S.L.